CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Anticoagulant selection in relation to the SAMe-TT\u3csub\u3e2\u3c/sub\u3eR\u3csub\u3e2\u3c/sub\u3e score in patients with atrial fibrillation: The GLORIA-AF registry
Authors
Dzifa Wosornu Abban
Nasser Abdul
+15 more
Atilio Marcelo Abud
Fran Adams
Srinivas Addala
Pedro Adragão
Walter Ageno
Hans Christoph Diener
Venkatesh K. Gurusamy
Jonathan L. Halperin
Menno V. Huisman
Gregory Y.H. Lip
Sabrina Marler
George Ntaios
Brian Olshansky
Christine Teutsch
Milla Thompson
Publication date
1 January 2021
Publisher
'Elsevier BV'
Doi
Cite
Abstract
© 2020 Hellenic Society of Cardiology Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores \u3e2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores \u3e2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score \u3e2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores \u3e2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores \u3e2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007
Similar works
Full text
Available Versions
George Washington University: Health Sciences Research Commons (HSRC)
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:hsrc.himmelfarb.gwu.edu:sm...
Last time updated on 19/04/2021